Table 2 The relationship between clinico-pathological characteristics and ER status of patients with primary operable invasive ductal breast cancer
|  | Oestrogen receptor negative (n = 124) | Oestrogen receptor positive (n = 237) | ( P-value) |
|---|---|---|---|
Age (≤50/>50 years) | 43/81 | 52/185 | 0.009 |
Size (≤20/21-50/>50 mm) | 57/62/4 | 149/83/5 | 0.004 |
Grade (I/II/III) | 3/22/99 | 61/125/51 | <0.001 |
Involved lymph node (0/1-3/>3) | 65/30/28 | 130/68/35 | 0.211 |
Progesterone -receptor status (PR-/PR+) | 117/5 | 72/161 | <0.001 |
HER-2 status (HER-2 -/HER-2+) | 80/41 | 212/24 | <0.001 |
Ki-67 status (Low Ki-67/High Ki-67) | 99/24 | 160/68 | 0.036 |
LVI (Absent/Present) | 56/68 | 161/76 | <0.001 |
MVD (CD34+) (tertiles 1, 2, 3) | 38/41/44 | 83/84/61 | 0.106 |
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy) | 44/80 | 89/148 | 0.699 |
Systemic treatment (ER-based treatment) (hormonal/hormonal + chemotherapy/chemotherapy/none) | 26/19/66/11 | 158/61/8/8 | <0.001 |
Cancer specific survival (months)* | 130 (118–142) | 156 (150–162) | 0.001 |